Nevertheless, the pathognomonic NAB2–STAT6 oncogenic fusion that induces IGF-1 overexpression and angiogenesis in the tumor microenvironment might help considering SFT as a targetable sarcoma. The gene discussed is IGF1; the disease is sarcoma.